Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics
about
Long-term delivery of protein therapeuticsIdentification and monitoring of host cell proteins by mass spectrometry combined with high performance immunochemistry testingCharacterizing monoclonal antibody structure by carbodiimide/GEE footprintingOrigin and prediction of free-solution interaction studies performed label-free.Enhancing the quality of H/D exchange measurements with mass spectrometry detection in disulfide-rich proteins using electron capture dissociation.Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications.Future of sustained protein delivery.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.Emerging mass spectrometry-based approaches to probe protein-receptor interactions: focus on overcoming physiological barriersQUDeX-MS: hydrogen/deuterium exchange calculation for mass spectra with resolved isotopic fine structure.Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance.Transferrin as a model system for method development to study structure, dynamics and interactions of metalloproteins using mass spectrometryAn improved fast photochemical oxidation of proteins (FPOP) platform for protein therapeutics.Advanced mass spectrometry workflows for analyzing disulfide bonds in biologics.Conformational analysis of therapeutic proteins by hydroxyl radical protein footprintingA novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines.Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting.Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.An 18O-labeling assisted LC/MS method for assignment of aspartyl/isoaspartyl products from Asn deamidation and Asp isomerization in proteinsAnalytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodiesHydrogen-exchange mass spectrometry for the study of intrinsic disorder in proteins.High-resolution MS for structural characterization of protein therapeutics: advances and future directions.Applications of capillary electrophoresis in characterizing recombinant protein therapeutics.Conformational effects in protein electrospray-ionization mass spectrometry.A novel rapid analysis using mass spectrometry to evaluate downstream refolding of recombinant human insulin-like growth factor-1 (mecasermin).Evaluation of Gallium as a Tracer of Exogenous Hemoglobin-Haptoglobin Complexes for Targeted Drug Delivery Applications.Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics.Characterizing monoclonal antibody structure by carboxyl group footprinting.Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestionAn Efficient and Rapid Method to Monitor the Oxidative Degradation of Protein Pharmaceuticals: Probing Tyrosine Oxidation with Fluorogenic Derivatization.Multi-step conformational transitions in heat-treated protein therapeutics can be monitored in real time with temperature-controlled electrospray ionization mass spectrometry.Mapping the Interactions of Selective Biochemical Probes of Antibody Conformation by Hydrogen-Deuterium Exchange Mass Spectrometry.A new strategy of using O18-labeled iodoacetic acid for mass spectrometry-based protein quantitation.A new liquid chromatography-mass spectrometry-based method to quantitate exogenous recombinant transferrin in cerebrospinal fluid: a potential approach for pharmacokinetic studies of transferrin-based therapeutics in the central nervous systems.Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches.The NISTmAb tryptic peptide spectral library for monoclonal antibody characterization.The heights of biopharmaceutical complexity and the current reach of analytical instrumentation.Deciphering the Biophysical Effects of Oxidizing Sulfur-Containing Amino Acids in Interferon-beta-1a using MS and HDX-MS.Characterization of a PEGylated protein therapeutic by ion exchange chromatography with on-line detection by native ESI MS and MS/MS.
P2860
Q26860505-A3AD5CB8-6361-41F6-8E06-5D4F80AA6BE5Q28535450-AA45334F-BD83-4DE6-A4AF-3B72CF8C2FD9Q30369478-2694D299-4DB2-4D93-B7FE-67415AFC89EAQ31056191-177A3F1D-96D5-4B7D-93EF-063CD621296FQ33732576-BDD7730E-7C50-417C-AE41-DA251AFE3223Q33844511-112EB0AE-6B3D-484C-8129-A7309076C446Q33924879-89981031-664F-4BBD-94F0-F379BB618970Q34489424-717C926B-74B0-4D1F-9726-DD1A98CD80AFQ34691652-F7742896-D4AA-4A88-BC65-DE9E15FB7382Q34761914-93F5C32F-A0D9-4F6A-B943-0EAC733C974AQ35164795-B39128BC-467E-4FB0-AED8-086966A2431AQ35511065-FFF5C410-84C0-4BB6-AEB1-F6001B74B8C1Q35528871-7CD870D5-CB02-4F48-B0E4-8DB64BEE5BA5Q35568366-A2C213C6-8BC7-468C-B212-8743D6E6DE7BQ35888367-681261DB-0627-4DBF-A88C-6E79EF11E388Q36588710-514EB098-61F3-43E5-A723-DAA1B81854C3Q36588729-C08C6B67-1B18-46AB-91BA-04DA625DA773Q36824142-8BBB27DD-6EF1-44F5-B35A-2AD71766646BQ36984283-5F648220-6AA7-4A0B-BD13-46A681619A48Q37022207-B0B0CF99-08D3-4896-B118-4CABCB926D90Q37567087-2C1E2CA7-E3DE-4571-8CBE-589B18D8310BQ38055634-CF3552B5-53B1-483E-B3B4-CDA02B67912BQ38110611-F221381E-20F5-44B6-AD23-FC8E0214BABAQ38152378-9AD33E09-5E2B-4614-B118-F7E4A00BE7AFQ38465322-61239665-6591-4D1F-9C2A-AFBD76087247Q38775433-F650744D-ED35-43D5-93B0-CD370CB6AE61Q40505663-026205D2-60F8-4D34-8AE5-1EF8A034A722Q40724867-1C8D0480-14C6-4840-A728-93A1E104E086Q40987519-B459AC2C-A479-436B-985A-259DC3FD36D0Q42081044-3153A58D-468D-40BE-9079-2A2437C898B4Q46149367-416C32CC-B1FA-4261-AE64-8B04DD39439CQ47230430-C25265D0-74A3-4D8A-8B00-4542EFA565DBQ48356441-826B324F-36C1-4B06-B6AC-B5B40867CEBCQ49164087-ADFBE5E4-687B-4237-8493-0FFA0411DDD8Q49884159-EA7BFAE2-5C4E-4EA6-ABE3-14511C982417Q49965683-198361B4-588D-425A-8629-C17CF647A2CEQ50100063-B506AD06-6140-4560-9979-769C10EB871FQ50874659-94F7DFBD-3535-40BB-A445-DC2B7B5EEC87Q51138751-C826C6F3-F88A-4A4D-A246-09DCC0220D77Q51268017-2628846A-7161-4889-AF18-881AC79E3B34
P2860
Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Advances and challenges in ana ...... havior of protein therapeutics
@ast
Advances and challenges in ana ...... havior of protein therapeutics
@en
type
label
Advances and challenges in ana ...... havior of protein therapeutics
@ast
Advances and challenges in ana ...... havior of protein therapeutics
@en
prefLabel
Advances and challenges in ana ...... havior of protein therapeutics
@ast
Advances and challenges in ana ...... havior of protein therapeutics
@en
P2093
P2860
P1476
Advances and challenges in ana ...... havior of protein therapeutics
@en
P2093
Burcu Baykal
Cedric E Bobst
Guanbo Wang
Igor A Kaltashov
Rinat R Abzalimov
Shunhai Wang
P2860
P304
P356
10.1016/J.BIOTECHADV.2011.05.006
P577
2011-05-17T00:00:00Z